Dr. Reddy’s Plans Calibrated Emerging Markets Redux
This article was originally published in PharmAsia News
Enthused by growth opportunities, the Indian drug maker is drawing up plans for a re-entry in certain key emerging markets. The renewed outlook comes at the back of an earlier deal with GSK, which experts believe did not reach anywhere near the potential expected from it.
You may also be interested in...
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.
India’s top regulatory agencies are weighing up the findings from a study it had commissioned that looks at the clinical benefits of heart stents, with the possible aim of using the results to back the use of cheaper, locally-produced devices.